His primary areas of study are Internal medicine, Melanoma, Oncology, Cancer and Cancer research. His research integrates issues of Immune system, Immunotherapy, Biopsy and Drug resistance in his study of Melanoma. His Oncology research is multidisciplinary, relying on both Antibody, Dabrafenib and Neuroblastoma RAS viral oncogene homolog.
His research investigates the connection with Cancer and areas like Biomarker which intersect with concerns in Tumor-infiltrating lymphocytes and Carcinoma. His biological study spans a wide range of topics, including Anti pd 1, Toxicity and MAPK/ERK pathway. Douglas B. Johnson has researched Ipilimumab in several fields, including CTLA-4 and Nivolumab.
His primary areas of study are Melanoma, Internal medicine, Cancer research, Oncology and Cancer. His studies deal with areas such as Immunology, Immune system, Immunotherapy, Targeted therapy and Neuroblastoma RAS viral oncogene homolog as well as Melanoma. In general Internal medicine study, his work on Ipilimumab, Adverse effect and Pembrolizumab often relates to the realm of In patient, thereby connecting several areas of interest.
His work carried out in the field of Ipilimumab brings together such families of science as Nivolumab, Clinical trial and Surgery. His research in Cancer research intersects with topics in Immune checkpoint, Trametinib, MAPK/ERK pathway and Mutation. His Cancer research includes themes of Bioinformatics, Intensive care medicine, Antibody, Biomarker and Fulminant.
His scientific interests lie mostly in Internal medicine, Melanoma, Cancer, Adverse effect and Oncology. His research in the fields of Ipilimumab, Nivolumab and Retrospective cohort study overlaps with other disciplines such as In patient. His Melanoma study is concerned with the larger field of Cancer research.
Douglas B. Johnson combines subjects such as Fulminant, Disease, Immune system and Intensive care medicine with his study of Cancer. Douglas B. Johnson has included themes like Discontinuation, Myocarditis, Incidence, Pneumonitis and Immunotherapy in his Adverse effect study. His study looks at the relationship between Oncology and topics such as Clinical endpoint, which overlap with Trametinib, Cohort study and Cohort.
His main research concerns Internal medicine, Adverse effect, Melanoma, Cancer and In patient. His Internal medicine research incorporates elements of Gastroenterology and Oncology. His Adverse effect research integrates issues from Body mass index and Myocarditis.
Melanoma is the subject of his research, which falls under Cancer research. His study in Cancer research is interdisciplinary in nature, drawing from both Targeted therapy, CDKN2A, Growth inhibition, Neuroblastoma RAS viral oncogene homolog and PTEN. His work deals with themes such as Quality of life, Blood pressure, Renal cell carcinoma, Lung cancer and Type 2 diabetes, which intersect with Cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias.
The New England Journal of Medicine (2016)
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Hubing Shi;Willy Hugo;Xiangju Kong;Aayoung Hong.
Cancer Discovery (2014)
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries;John F. Thompson;Alistair J. Cochran;Robert H. Andtbacka.
The New England Journal of Medicine (2017)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra.
JAMA Oncology (2018)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson.
Annals of Oncology (2016)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo;Hubing Shi;Lu Sun;Marco Piva.
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi;Joe Elie Salem;Jeffrey A. Sosman;Bénédicte Lebrun-Vignes.
The Lancet (2018)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: